

Whole genome sequencing analysis of *Enterococcus faecium* clinical isolates reveals high strain diversity and accurate prediction of antimicrobial resistance

Melis Anahtar¹, Juliet Bramante², Jiawu Xu², Lisa Desrosiers¹, Eric Rosenberg¹, Virginia Pierce^{1,*}, Douglas Kwon^{2,*}

¹Department of Pathology, Massachusetts General Hospital; ²Ragon Institute of MGH, MIT, and Harvard; Boston, MA, USA

Contact Information


Melis Anahtar, MD, PhD

✉ manahtar@mgh.harvard.edu

🐦 [melisaanahtar](https://twitter.com/melisaanahtar)

* contributed equally


1- Background on *E. faecium*



- » Gram-positive bacterium with 2.5 - 3.1 Mb genome size.
- » A major cause of hospital-acquired infections.
- » Difficult to treat, due to high rates of multidrug resistance.
- » Whole genome sequencing (WGS) is a powerful tool to uncover transmission patterns and antimicrobial resistance (AMR) mechanisms of *Enterococcus faecium*, but most *E. faecium* genomic studies focus on isolates from outbreak investigations rather than routine sampling.
- » The use of WGS to predict *E. faecium* AMR has not been tested systematically.
- » Here we use WGS to characterize over 400 unique *E. faecium* clinical isolates to assess their strain diversity and AMR mechanisms.

2- Methods


Derivation set



Validation set



3- Results: High diversity and novel STs



- » >85% of DS and 75% of VS isolates belonged to hospital-associated clonal complex (CC) 17, most frequently ST736, ST18, ST412, ST17, and ST117.
- » The sixth most common MLST type was novel (now ST1578), most closely related to ST117.
- » The DS also included 12 unique isolates of an additional novel type (now designated ST1579), most closely related to ST17 and predominantly found in rectal screening samples.

4- Results: Accurate rules-based predictions

Antimicrobial Drug	Genotype used for prediction	Overall suscep. rate	Categorical agreement	Very major error rate (FN) (95% CI)	Major error rate (FP) (95% CI)	PPV	NPV
Ampicillin	Mutation of <i>pbp5</i> 485M	13%	98.9%	1.1% (0.13, 4.0)	0% (0, 13)	100.0%	92.8%
Vancomycin	Presence of <i>vanA</i> or <i>vanB</i>	21%	99.0%	0.0% (0, 2.2)	2.3% (0.06, 12)	99.4%	100.0%
Gentamicin high-level	Presence of <i>aac(6)-Ie-aph(2'')-Ia</i>	95%	100.0%	0.0% (0, 28)	0.0% (0, 1.9)	100.0%	100.0%
Ciprofloxacin*	Mutation of <i>gyrA</i> 84S or <i>parC</i> 82S	15%	100.0%	0.0% (0, 2.1)	0.0% (0, 11)	100.0%	100.0%
Levofloxacin*	Mutation of <i>gyrA</i> 84S or <i>parC</i> 82S	15%	100.0%	0.0% (0, 2.0)	0.0% (0, 11)	100.0%	100.0%
Tetracycline	Presence of <i>tetL</i> , <i>tetM</i> , or <i>tetS</i>	24%	96.1%	0.0% (0, 2.3)	14% (5.8, 27)	95.7%	100.0%
Doxycycline	Presence of <i>tetM</i>	28%	90.8%	1.4% (0.16, 4.8)	27% (16, 40)	90.1%	95.6%
Linezolid	Mutation of 23S rRNA G2576T	99%	n/a	n/a	n/a	n/a	n/a

- » After resolving genotyping or phenotyping errors, the genotypic-phenotypic categorical agreement was generally excellent. All drugs surpassed the FDA performance metric of a percent categorical agreement above 89.9%.
- » The very major error (VME) rate, also known as the false negative rate, was 1.4% or lower for all drugs.

5- Conclusions

- » In a diverse and challenging set of clinical *E. faecium* isolates, known AMR genes and SNPs can be simply applied to predict phenotypic susceptibility with an average categorical agreement of 97.8% across seven commonly used antibiotics.
- » Our findings can be used to improve molecular VRE screening methods and existing WGS-based bioinformatics tools.

6- Acknowledgements

We are very grateful to all of the Microbiology laboratory technologists, Dr. Fatima Hussain for her sequencing assistance, Dr. Matthew Hayward for sharing his genomic expertise, Dr. Seth Bloom for his clinical insights, and Drs. Sarah Turbett and John Branda for their microbiologic expertise and support.

7- References

- Baym et al. "Inexpensive multiplexed library preparation for megabase-sized genomes." *PLoS One*, 2015.
- PubMLST, <https://pubmlst.org/efaecium>
- Inouye et al. "SRST2: Rapid genomic surveillance for public health and hospital microbiology labs." *Genome Medicine*, 2014.